BIO, PhRMA, others seek tweaks to FDA draft guidance on diversity in postmarketing studies
After the FDA published draft guidance over the summer on postmarketing approaches to collecting data from underrepresented groups, stakeholder groups largely welcomed the FDA’s proposals …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
